In less than two decades, Internet and mobile phones have revolutionized our communication methods. The health sector has eagerly embraced these new technologies. Computerized exchange of medical data has facilitated telemedicine exchange protocols, and mobile phones have increased access to medical information among the general public. Countless amounts of smartphone health apps have been released. Today, medical use of new technologies has become a fully-fledged field of scientific research.
Engineers, bio-statisticians, and clinicians are working together to develop new forms of telemedicine that serve patients and health professionals. Connected devices are the latest innovation in this ongoing revolution. The increasing miniaturization of sensors and the spread of smartphones have spurred the growth of new tools, which make it easier for people to monitor their health data on the go and share it with medical professionals if they so choose. Big data, analytics, and machine learning support this evolution, moving healthcare from cure to pre-empt and pushing remote patient care.
At this event, attendees from the medical world, pharma, research, and ICT communities will gather for an afternoon of discussions, demos, and networking. Speakers will include executives and experts from organizations such as Johnson & Johnson, imec, and Nokia. Visit the demonstration area and discover how new services and experiences can support you in building a better and smarter connected world.
The event will take place at the Nokia offices, Copernicuslaan 50, 2018 Antwerp, from 13h30 till 18h00.
More detailed information on the event and the agenda will follow in a few weeks. Make sure to save the day & reserve a seat using this link https://www.eiseverywhere.com/ehome/index.php?eventid=286579&
Do note that your reservation is only tentative at this stage. Final confirmations will be provided during November based on the number of seats available.
October 5, 2017
BeCRO has set up and coordinates, with the cabinet of Maggie De Block, FAMHP, FlandersBio, BioWin, Lifetech Brussels, BRAS and several top Pharma companies, a lobbying group on “Virtual Clinical trials and Direct to Patient Shipments”. This working group has conducted a survey on Direct to Patient Shipments among 4 target audiences: Patients, Sponsors, Investigator Sites, CROs/CMOs.
Here the results that were presented by our Board Member during the FAMHP symposium on September 26 in Brussels.
Direct to Patient (D2P) shipment for Clinical Trials - Survey
May 15, 2017
Dear Sponsor, Dear CRO, Dear Patient, Dear Investigator
In Europe and more specifically Belgium, Direct To Patient (D2P) shipments are limited within the current regulatory framework. Considering the growing enthusiasm of pharma companies, investigators and patients for D2P shipments in the USA, we want to investigate if the European market should not consider adapting its regulations in order to respond to this new demand.
A working group has been established with the participation of the Belgian Federal Agency for Medicines and Health Products (FAMHP), the Ministry of Social Affairs & Public Health, Patient organizations, the Industry, Academic Organizations and finally Industry Associations to further explore these options and understand the regulatory implications.
This working group is reaching out to you as stakeholder in Clinical Trials, so that you may share your experiences and show your future interest on D2P by completing this questionnaire.
The survey will help us define and scope the needs of D2P shipments in EU and help us support a change in the current regulations so that we can better meet the evolving needs of patients participating in clinical trials.
Thank you for taking the time to answer this questionnaire by 31st July 2017.
For the purpose of this questionnaire, D2P means shipments of IMP from a clinical site to a patient, from a pharmacy to a patient or shipments from a depot to a patient.
For the purpose of this questionnaire, Company refers to the whole organization (on a global scale). Some questions refer to previous experience with D2P that may exist within your organization at an international level.
It is possible that answering this questionnaire may require the input of several different business units of your organization. We would appreciate it if you could consolidate the information of your colleagues and provide a company-wide response to the questionnaire.
Your feedback will be treated anonymously.
If you wish to receive the survey’s output, you can of course provide your email.
https://www.surveymonkey.co.uk/r/D2PSponsor (Sponsor Survey)
https://www.surveymonkey.co.uk/r/6TV6MQX (Patient Survey)
https://www.surveymonkey.co.uk/r/RYSM8WYCRO (CRO Survey)
https://www.surveymonkey.co.uk/r/VQHSKX2Investigators (Investigator Survey)
The D2P Working Group